Ken Griffin Nanobiotix S.A. Put Options Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
Put Options
0 transactions
Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
---|
Others Institutions Holding NBTX
# of Institutions
15Shares Held
6.49MCall Options Held
0Put Options Held
0-
Johnson & Johnson New Brunswick, NJ5.62MShares$22.7 Million10.31% of portfolio
-
Perceptive Advisors LLC New York, NY555KShares$2.24 Million0.08% of portfolio
-
Black Rock Inc. New York, NY239KShares$963,2020.0% of portfolio
-
Old Mission Capital LLC48.5KShares$195,3500.0% of portfolio
-
Goldman Sachs Group Inc New York, NY10.5KShares$42,3060.0% of portfolio
About Nanobiotix S.A.
- Ticker NBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,875,900
- Market Cap $141M
- Description
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cance...